Intravenous Tenecteplase for Acute Ischemic Stroke Within 4.5–24 Hours of Onset (ROSE-TNK): A Phase 2, Randomized, Multicenter Study

BACKGROUND AND PURPOSE: Intravenous tenecteplase (TNK) efficacy has not been well demonstrated in acute ischemic stroke (AIS) beyond 4.5 hours after onset. This study aimed to determine the effect of intravenous TNK for AIS within 4.5 to 24 hours of onset. METHODS: In this pilot trial, eligible AIS...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lu, Dai, Ying-Jie, Cui, Yu, Zhang, Hong, Jiang, Chang-Hao, Duan, Ying-Jie, Zhao, Yong, Feng, Ye-Fang, Geng, Shi-Mei, Zhang, Zai-Hui, Lu, Jiang, Zhang, Ping, Zhao, Li-Wei, Zhao, Hang, Ma, Yu-Tong, Song, Cheng-Guang, Zhang, Yi, Chen, Hui-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Stroke Society 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10574303/
https://www.ncbi.nlm.nih.gov/pubmed/37608533
http://dx.doi.org/10.5853/jos.2023.00668

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10574303/
https://www.ncbi.nlm.nih.gov/pubmed/37608533
http://dx.doi.org/10.5853/jos.2023.00668

Ejemplares similares